CN108350445A - 肿瘤免疫治疗 - Google Patents

肿瘤免疫治疗 Download PDF

Info

Publication number
CN108350445A
CN108350445A CN201680035950.5A CN201680035950A CN108350445A CN 108350445 A CN108350445 A CN 108350445A CN 201680035950 A CN201680035950 A CN 201680035950A CN 108350445 A CN108350445 A CN 108350445A
Authority
CN
China
Prior art keywords
mirna
cells
promoter
nucleic acid
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680035950.5A
Other languages
English (en)
Chinese (zh)
Inventor
蒂莫西·冠-塔·卢
利奥尔·尼西姆
吴名儒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of CN108350445A publication Critical patent/CN108350445A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
CN201680035950.5A 2015-06-19 2016-06-17 肿瘤免疫治疗 Pending CN108350445A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562181906P 2015-06-19 2015-06-19
US62/181,906 2015-06-19
US201662325314P 2016-04-20 2016-04-20
US62/325,314 2016-04-20
PCT/US2016/038222 WO2016205737A2 (en) 2015-06-19 2016-06-17 Tumor immunotherapy

Publications (1)

Publication Number Publication Date
CN108350445A true CN108350445A (zh) 2018-07-31

Family

ID=57546436

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680035950.5A Pending CN108350445A (zh) 2015-06-19 2016-06-17 肿瘤免疫治疗

Country Status (7)

Country Link
US (1) US20190002912A1 (enExample)
EP (1) EP3310915A4 (enExample)
JP (1) JP2018520669A (enExample)
CN (1) CN108350445A (enExample)
AU (1) AU2016279050A1 (enExample)
HK (1) HK1257177A1 (enExample)
WO (1) WO2016205737A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112654711A (zh) * 2018-08-29 2021-04-13 上海科技大学 Cas蛋白抑制剂的组合物及应用
CN116859048A (zh) * 2022-12-09 2023-10-10 上海交通大学医学院附属第九人民医院 肿瘤标志物跨膜蛋白slc31a1及其应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220890T1 (hr) 2015-02-06 2022-10-14 National University Of Singapore Postupci za povećanje učinkovitosti terapijskih imunosnih stanica
CN110073000A (zh) 2016-07-26 2019-07-30 森迪生物科学公司 遗传擦除子
CN110582574A (zh) * 2017-03-13 2019-12-17 麻省理工学院 合成启动子
CA3071282A1 (en) 2017-08-10 2019-02-14 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
US12398428B2 (en) * 2019-02-06 2025-08-26 Cornell University DARC expression as prognosticator of immunotherapy outcomes
US20230272035A1 (en) * 2019-12-05 2023-08-31 Vycellix, Inc. Modulators of the immune escape mechanism for universal cell therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20100197006A1 (en) * 2007-04-25 2010-08-05 President And Fellows Of Harvard College Molecular circuits
US20130101558A1 (en) * 2010-04-23 2013-04-25 University Of Massachusetts Aav-based treatment of cholesterol-related disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20100197006A1 (en) * 2007-04-25 2010-08-05 President And Fellows Of Harvard College Molecular circuits
US20130101558A1 (en) * 2010-04-23 2013-04-25 University Of Massachusetts Aav-based treatment of cholesterol-related disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KUANG-WEN LIAO等: "Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity", 《CANCER GENE THERAPY》 *
ZHEN XIE等: "Multi-input RNAi-based logic circuit for identification of specific cancer cells", 《SCIENCE》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112654711A (zh) * 2018-08-29 2021-04-13 上海科技大学 Cas蛋白抑制剂的组合物及应用
CN112654711B (zh) * 2018-08-29 2024-03-26 上海科技大学 Cas蛋白抑制剂的组合物及应用
CN116859048A (zh) * 2022-12-09 2023-10-10 上海交通大学医学院附属第九人民医院 肿瘤标志物跨膜蛋白slc31a1及其应用

Also Published As

Publication number Publication date
US20190002912A1 (en) 2019-01-03
JP2018520669A (ja) 2018-08-02
HK1257177A1 (zh) 2019-10-18
WO2016205737A3 (en) 2017-02-02
EP3310915A4 (en) 2019-04-10
AU2016279050A2 (en) 2018-01-04
AU2016279050A1 (en) 2018-01-04
EP3310915A2 (en) 2018-04-25
WO2016205737A2 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
US20250101079A1 (en) T cell receptors with mage-b2 specificity and uses thereof
US20190002912A1 (en) Tumor immunotherapy
JP7710644B2 (ja) 複数の抗原を標的とするｃｏｍｐｏｕｎｄキメラ抗原受容体（ｃＣＡＲ）の組成物およびその使用方法
ES2875959T3 (es) Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión
ES2877367T3 (es) Elementos reguladores postranscripcionales de hepatitis modificados
KR102935974B1 (ko) 키메라 항원 수용체 및 이의 용도
KR102338993B1 (ko) 인위적으로 조작된 조작면역세포
CN111093679A (zh) 用于条件调控基因表达的方法和系统
JP2019527563A (ja) 時空間調節因子
EP4365193A1 (en) Chimeric polypeptide for regulating cell physiological activity
Li et al. Precision sniper for solid tumors: CAR-NK cell therapy
CN115948344A (zh) 嵌合抗原受体nk细胞、制备方法及其用途
Lazarova et al. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system
KR20210150446A (ko) 종양 항원 인식 수용체를 함유하는 면역 세포 및 이의 적용
Dash et al. Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review
Yin et al. Translating synthetic gene circuits into the clinic: Challenges, opportunities, and future directions
JP2023549780A (ja) 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
CN118497126A (zh) 针对癌症个体化疗法的制品和方法
KR20230040364A (ko) 키메라 항원 수용체 및 이의 용도
Chen et al. Synthetic immunity to break down the bottleneck of cancer immunotherapy
Bhattacharyya et al. Lung Cancer Immunotherapy Approaches: From Clinical Testing to Future Advances
CN111629737A (zh) T细胞信号传导的miRNA调节及其应用
Chen Outsmarting and Outmuscling Cancer Cells for Next-Generation CAR-T Cell Therapies
WO2025158400A1 (en) Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy
Park Discovery of Novel Cancer Immunotherapy Targets with Next Generation Genome Engineering Methods

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1257177

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180731

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1257177

Country of ref document: HK